Ann Pharmacol Pharm | Volume 5, Issue 6 | Review Article | Open Access

The Potential Host Directed Therapy in Tuberculosis and COVID-19

Bernadette Dian Novita^1*, Ferdinand Erwin², Davin Raharja² and Alyssa Claudia Valerie Gunawan²

¹Department of Pharmacology and Therapy, Widya Mandala Catholic University, Indonesia
²Widya Mandala Catholic University, Indonesia

^*Correspondance to: Bernadette Dian Novita 

Fulltext PDF

Abstract

World Health Organization (WHO) on April 2020 stated that patient with both tuberculosis and COVID-19 may have poorer treatment outcomes. The COVID-19 and tuberculosis both primarily affect the lungs and show similar symptoms such as cough, fever, and severe lower track respiratory syndromes. Even the biological agents and incubation period from exposure to disease are different. Understanding the fundamental CD4+ T-cells exhaustion role in underlying the clinical manifestations of COVID-19 and tuberculosis is vital for the identification and rational design of effective therapies. Here, the perspective of how anti TNF and IL-6 antagonist agents could be the potential rational host directed therapy in tuberculosis and COVID-19.

Keywords:

Tuberculosis; COVID-19; Host directed therapy; CD4+; WHO

Citation:

Novita BD, Erwin F, Raharja D, Gunawan ACV. The Potential Host Directed Therapy in Tuberculosis and COVID-19. Ann Pharmacol Pharm. 2020;5(6):1197..